NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
Biotechnology | Disease | FDA | Oncology | Therapeutics | Women's Health
Letrozole was approved by the FDA for the adjuvant treatment of early-stage breast cancer after five years of tamoxifen therapy
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
World’s first use of low-dose radioactive palladium ‘seeds’ was used to treat breast cancer patients at the Women’s Research Institute in Toronto
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…
Women’s Health Initiative data showed women who take estrogen with hormone progestin have greater risk of developing breast cancer
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
A novel approach to treatment of solid cancers involved therapeutic agents that inhibit the generation of new blood vessels in growing tumors
On Nov. 19, 2003, a novel approach to treatment of solid cancers involved therapeutic agents that inhibit the…
A clinical trial found post-menopausal survivors of early-stage breast cancer who took letrozole reduced risk of cancer recurrence
On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who…
Death rates from the lung, breast, prostate, and colorectal cancers continued to decline in the late 1990s
On Sept. 3, 2003, the death rates from the four most common cancers, – lung, breast, prostate, and…
First West Coast Baby born using frozen egg technique at OHSU
On Jul. 10, 2003, the University Fertility Consultants at Oregon Health & Science University (OHSU) announced they had…
University of Saskatchewan researchers discovered “follicular waves” in the human menstrual cycle
In July 2003, University of Saskatchewan researchers announced they had discovered “follicular waves” in the human menstrual cycle….
Stanford researchers found Antidepressant helped alleviate compulsive shopping disorder
On Jun. 16, 2003, researchers at Stanford University Medical Center announced they found that a drug commonly prescribed…
Data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial was announced
On Jun. 5, 2003, data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial gave fresh insight…
NCI funded trial showed postmenopausal women who used estrogen replacement therapy were at higher risk of developing ovarian cancer
On Jul. 17, 2002, a National Cancer Institute funded trial showed that postmenopausal women who used estrogen replacement…
Dr. Julie Louise Gerberding became the first woman Director of the U.S. Centers for Disease Control and Prevention
On Jul. 3, 2002, Dr. Julie Louise Gerberding, M.D., M.P.H., became the first woman Director of the U.S….
Scientists from NCI and FDA reported that patterns of proteins found in patients’ serum may reflect the presence of ovarian cancer
On Feb. 7, 2002, scientists from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA)…
Los Angeles Cancer Center Received $15 Million for Woman’s Health Center
On Mar. 26, 2005, The University of Southern California/Norris Comprehensive Cancer Center in Los Angeles announced a $15…
National Cancer Institute and ACRIN launched first multicenter study to compare digital mammography
On Sept. 4. 2001, the National Cancer Institute (NCI) and the American College of Radiology Imaging Network launched…
OMRF researchers found that BRCA1 and BRCA2 genes may predict breast cancer risk in women
On May 24, 2001, Dr. Eldon Jupe and a team of Oklahoma Medical Research Foundation (OMRF) researchers found…
Compulsive shopping research at Stanford seeks to treat mysterious disorder
On Dec. 16, 2002, researchers at Stanford University Medical Center announced they were continuing a multi-year clinical trial…
The National Center on Birth Defects and Developmental Disabilities (NCBDDD) was established at CDC
On Oct. 17, 2001, the National Center on Birth Defects and Developmental Disabilities (NCBDDD) was established at the…
Regional Cancer Coalitions of Georgia Created
In 2001, the Regional Cancer Coalitions of Georgia were created by the General Assembly and Governor to ensure…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
President Bill Clinton signed into law the Semipostal Authorization Act
On Jul. 28, 2000, President Bill Clinton signed into law the Semipostal Authorization Act (P.L. 106-253), which gave…
Biotechnology | Disease | Medicine | NIH | Therapeutics | Women's Health
President Clinton directed Medicare program to reimburse providers for cost of routine patient care in clinical trials
On Jun. 7, 2000, President Clinton issued an Executive Memorandum that directed the Medicare program to revise its…
NeoPath merged with AutoCyte to create TriPath Imaging
On Jun. 7, 1999, NeoPath merged with AutoCyte to form TriPath Imaging based in Burlington, N.C. NeoPath was…
The Study of Tamoxifen and Raloxifene began recruiting volunteers
On May 25, 1999. the Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer…
Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer prevention
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
Breast Cancer Prevention Trial Results published
On Sept. 14, 1998, researchers from the Breast Cancer Prevention Trial (BCPT) published a full report and update…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Stamp Out Breast Cancer stamp was first issued
On Jul. 29, 1998, the Stamp Out Breast Cancer stamp was first issued. The driving force behind the…
Biotechnology | Diagnostics | Disease | Medical Device | Oncology | Radiology | U.S. Congress | Women's Health
Mammography Quality Standards Reauthorization Act continued 1992 Act until 2002
In 1998, the Mammography Quality Standards Reauthorization Act (MQSA) was passed by the U.S. Congress and continued the…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Stamp Out Breast Cancer Act (PL 105-41) was signed into law
On Aug. 13, 1997, the Stamp Out Breast Cancer Act (PL 105-41) was signed into law by President…